TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Simplified Antibiotic Therapy for Sepsis in Young Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion Criteria~  * Infants 0-59 days old who are residents of catchment population of the study hospitals or clinics~ * One or more of the following five signs: severe chest in-drawing, axillary temperature \>38.0C or \<35.50 C, movement only when stimulated, and history of feeding problems (confirmed by poor suck on feeding assessment)~ * Family refuses recommended hospitalization or hospitalization otherwise not feasible~ * Informed consent by a legal guardian.~* Exclusion Criteria:~Very severe infection/disease characterized by presence of any of the following signs (unconscious, convulsions, unable to feed, apnea, unable to cry, cyanosis, bulging fontanel, prolonged capillary refill, major congenital malformations, major bleeding, surgical conditions needing hospital referral, persistent vomiting defined as vomiting following three attempts to feed the baby within ½ hour)~* Very low birth weight: weight \<1500~* Hospitalization for illness in the last two weeks~* Previous inclusion in the study

- Gender: ALL
- Minimum Age: None
- Maximum Age: 59 Days
- Healthy Volunteers: f

Study Arms:
- procaine penicillin and gentamicin (Type: ACTIVE_COMPARATOR): Procaine penicillin, 50,000 IU/kg by intramuscular injection plus gentamicin, 5 mg/kg intramuscular injection, both given once daily for 7 days
- Amoxicillin and gentamicin (Type: EXPERIMENTAL): Oral amoxicillin (80-90 mg/kg) divided twice daily and intramuscular gentamicin, 5 mg/kg once daily, both given for 7 days
- procaine penicillin, gentamicin, and amoxicillin (Type: EXPERIMENTAL): procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals aged 18 years and older who voluntarily decide to participate in this study and provide written informed consent~* Female of childbearing potential who agree to use medically allowed methods of contraception during the study period~* Individuals who agrees not to perform blood donation and transfusion during the study period~Exclusion Criteria:~* Individual being considered to be confirmed COVID-19~* Direct contact with COVID-19 infected person within 14 days prior to the 1st dose of the IP~* Individuals at high risk of exposure to SARS-CoV-2~* Individuals with clinically significant abnormalities in clinical laboratory tests, ECGs, and chest X-ray during screening~* Individuals with fever within 72 hours prior to the 1st dose of the IP or suspected other infectious disease or symptoms associated with other infectious disease~* Individuals with serious medical or psychiatric disease~* History of SARS-CoV or MERS-CoV infection~* History of allergic reaction or hypersensitivity reactions to any of components of the IP~* History of serious adverse events, serious allergic reaction or serious hypersensitivity reactions to vaccination~* History of receiving organ or bone marrow transplant~* Suspected or history of drug abuse or alcohol abuse within 6 months prior to vaccination~* History of vaccination against SARS-CoV, MERS-CoV, or SARS-CoV-2~* History of vaccination with test vaccine substance~* Treatment with immunosuppressants or immune modifying drugs~* History of treatment with antipsychotics or opioid dependence~* Pregnant or lactating women~* Other reasons based on which the individual is considered to be ineligible for this study in the opinion of the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Test group(EuCorVac-19) - Cohort A (Type: EXPERIMENTAL): Cohort A - Immunogenicity cohort
- Comparator group(ChAdOx1) - Cohort A (Type: ACTIVE_COMPARATOR): Cohort A - Immunogenicity cohort
- Test group(EuCorVac-19) - Cohort B (Type: EXPERIMENTAL): Cohort B - Safety cohort
- Comparator group(ChAdOx1) - Cohort B (Type: ACTIVE_COMPARATOR): Cohort B - Safety cohort

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy in HIV Patients With Viral Suppression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of either sex (female or male) and 18 years or older.~* Patients seropositive for HIV-1 using standard diagnostic criteria.~* There is confirmation of viral load to be lower than 50 cop/ml during the 6 previous months to inclusion. The requirement is to have at least two viral loads lower than 50 cop/mL separated by 6 months and no one \>50cop/mL during the 6 months before inclusion.~* Patients on continuous HAART consisting of LPV/r, emtricitabine (FTC) or 3TC (lamivudine) and an NRTI for at least 2 months before being randomized in this study.~* Patients who are clinically stable, in the opinion of the investigator, at entry into the study (clinical status and chronic medication must not have not been modified at least 14 days prior to randomization). Patients receiving therapy for an active opportunistic infection are eligible for enrollment if the above criteria are met. Standard prophylaxis of opportunistic infections is permitted.~Exclusion Criteria:~* Pregnancy, nursing, or planned pregnancy during the study period.~* Previous failure with regimens including a protease inhibitor (PI) or 3TC/FTC.~* Known resistance mutations to PIs or 3TC/FTC.~* Patients with an active opportunistic infection or malignancy. Patients with a stable chronic opportunistic infection may be included in the study.~* Any disease or history of disease which, in the opinion of the investigator, might confound the results of the study or pose additional risk to patient treatment.~* Patients diagnosed with visceral Kaposi's sarcoma (KS), patients with lymphoedema secondary to cutaneous KS or cutaneous or palatine KS who have been treated with systemic immunosuppressive therapy must also be excluded.~* Patients with chronic hepatitis B on treatment with tenofovir + 3TC/FTC

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- simplification (Type: EXPERIMENTAL): Lopinavir/ritonavir (400/100 BID) plus lamivudine (300 QD)
- Continue with current treatment (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effectiveness of a Physiotherapy Technique in Patients With Chronic Myofascial Temporomandibular Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥18 years.~* Patients diagnosed of myofascial TMD with at least one TrP with referred pain.~* TMD patients with a current complaint of myofascial pain with more than 6 months of evolution.~* Patients with myofascial TMD initially treated with splint currently used, that has not been modified in the last 6 months, without improvement.~Exclusion Criteria:~* Patients treated with occlusal splint recently modified.~* Patients with acute TMJ diseases.~* Patients with systemic disease, neurological and muscular diseases.~* Patients with psychiatric or psychological disorders.~* Patients with cervical disc hernia and acute whiplash injury.~* Changes in the painkillers intake during the experiment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sham simulation group (Type: SHAM_COMPARATOR): A simulation of the pressure release technique, applying a soft pressure or contact in the same muscles sites or trigger points than in the intervention group.
- Pressure release technique group (Type: EXPERIMENTAL): The release pressure technique is applied in the trigger points of masticatory and neck muscles (upper trapezius, sternal and clavicular sternocleidomastoid, deep and superficial masseter, posterior, medium and anterior temporalis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cognitive Therapy for Recurrent Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Recurrent unipolar major depressive disorder~* Have experienced at least two episodes of major depression~* Have experienced at least one period of recovery during a depressive episode or have a history of dysthymia (a mood disorder characterized by depression) prior to the onset of current or past depressive episodes~* Willing and able to comply with all study requirements~* Able to speak and read English~Exclusion Criteria:~* Active alcohol or other substance dependence within 6 months prior to study entry~* Currently at risk for suicide~* Mood disorders due to a medical condition or substance abuse~* Bipolar, schizoaffective, obsessive compulsive, or eating disorders~* Schizophrenia~* Unable to stop mood-altering medications~* Current use of medication or diagnosis of a medical disorder that may cause depression (e.g., diabetes, head injury, stroke, cancer, multiple sclerosis)~* Previous failure to experience a reduction in depressive symptoms after 8 weeks of cognitive therapy with a certified therapist~* Previous failure to experience a reduction in depressive symptoms after 6 weeks of 40 mg of Prozac~* Pregnancy or plan to become pregnant in the next 11-12 months~* Unable to attend clinic twice weekly during business hours~* Unable to complete questionnaires

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Participants received acute phase and continuation phase cognitive therapy
- 2 (Type: PLACEBO_COMPARATOR): Participants received acute phase cognitive therapy and continuation phase pill placebo
- 3 (Type: ACTIVE_COMPARATOR): Participants received acute phase cognitive therapy and continuation phase fluoxetine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subject ≥18 years of age on the day of signing the ICF.~* A confirmed clinical diagnosis of CF and homozygous for the F508del CFTR mutation.~* Stable intake of physician prescribed Orkambi (lumacaftor 400 mg/ivacaftor 250 mg b.i.d.) for at least 12 weeks prior to the first study drug administration, and planned continuation of Orkambi for the duration of the study.~* FEV1 ≥40% of predicted normal for age, gender and height at screening (pre- or postbronchodilator).~* Sweat chloride concentration ≥60 mmol/L at screening.~Exclusion Criteria:~* History of serious allergic reaction to any drug as determined by the investigator (e.g., anaphylaxis requiring hospitalization) and/or known sensitivity to any component of the study drug.~* History of clinically meaningful unstable or uncontrolled chronic disease that makes the subject unsuitable for inclusion in the study in the opinion of the investigator.~* Unstable pulmonary status or respiratory tract infection (including rhinosinusitis) requiring a change in therapy within 4 weeks prior to the first study drug administration.~* History of hepatic cirrhosis with portal hypertension (e.g.,signs/symptoms of splenomegaly, esophageal varices, etc.).~* Abnormal liver function test at screening, defined as aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) and/or alkaline phosphatase and/or gammaglutamyl transferase (GGT) ≥3 x the upper limit of normal (ULN), and/or total bilirubin ≥1.5 x the ULN at screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GLPG2737 (Type: EXPERIMENTAL): GLPG2737 will be provided as capsules for oral use.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be provided as capsules for oral use.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, ages 18 and older~* Clinical history consistent with asthma~* For subjects regularly using inhaled corticosteroids, FEV1 50% of predicted, methacholine PC20 FEV1 16 mg/ml or 12% and 200 ml, improvement in FEV1 after 2 puffs of inhaled albuterol~* For subjects not regularly using inhaled corticosteroids, FEV1 40% of predicted, methacholine PC20 FEV1 8 mg/ml or 12% and 200 ml, improvement in FEV1 after 2 puffs of inhaled albuterol~* Genotype eligibility (determined during screening)~Exclusion Criteria:~* Smoker (total smoking history must be less than 10 pack years)~* Significant unstable medical condition other than asthma~* History of life-threatening asthma requiring treatment with intubation and mechanical ventilation in the past 10 years~* Pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- B16 Arg/Arg (Type: EXPERIMENTAL): B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone hydroflouroalkane (HFA), followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA
- B16 Gly/Gly (Type: EXPERIMENTAL): B16 Gly/Gly genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-label, Single-dose, Intravenous Administration Study of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females between 18 and 65 years of age~* Negative test for the selected drugs of abuse at screening~Hepatic impaired subjects:~* Stable hepatic function and medication regimen for at least 28 days prior to check-in~* Degree of hepatic impairment will be determined by the Child-Pugh Scale~Exclusion Criteria:~* Clinical manifestation of any disease (except hepatic impaired subjects)~* History of significant hypersensitivity, intolerance, or allergy to any drug compound, including food, or other substance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Subjects with moderate chronic hepatic impairment (Type: EXPERIMENTAL): Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
- Healthy subjects matched to moderate hepatic impaired subjects (Type: EXPERIMENTAL): Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
- Subjects with mild chronic hepatic impairment (Type: EXPERIMENTAL): Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
- Healthy subjects matched to mild hepatic impaired subjects (Type: EXPERIMENTAL): Single IV bolus of NO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
- Subjects with severe chronic hepatic impairment (Type: EXPERIMENTAL): Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of signed informed consent/ paediatric assent (if applicable) prior to any study specific procedures including medication withdrawal~* Male or Female, ≥12 years of age~* Documented clinical diagnosis of asthma for at least 1 year prior to Visit 2~* Patient must have history of at least 1 asthma exacerbation including one of the following:~  * requiring treatment with systemic corticosteroids~ * an asthma-related hospitalization between 4 weeks and 12 months prior to randomization~* Current Asthma Therapy: Patients must be appropriately using one of the treatments for asthma listed in the protocol combined with achieving certain results when recording an Asthma Control Questionnaire~Exclusion Criteria:~* Patient has a history of life-threatening asthma. Defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnea requiring non-invasive ventilatory support.~* Patient has required treatment with systemic corticosteroids (tablets, suspensions or injectable) for any reason within 4 weeks prior to Visit 2~* Patient has an ongoing exacerbation, defined as a worsening of asthma that requires treatment with systemic corticosteroids (tablets, suspension, or injectable)~* An asthma exacerbation within 4 weeks of randomization or more than 4 separate exacerbations in the 12 months preceding randomization or more than 2 hospitalizations for treatment of asthma in the 12 months preceding randomization~* Patient has a respiratory infection or other viral/bacterial illness, or is recovering from such an illness at the time of Visit 2 that, in the investigator's opinion, will interfere with the patient's lung function~* Patient must not meet unstable asthma severity criteria as listed in the protocol~* Peak expiratory flow must not be below 50% o predicted normal~* Pregnancy, breast-feeding or planned pregnancy during the study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Symbicort
- 2 (Type: ACTIVE_COMPARATOR): budesonide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MIC Cell Therapy for Individualized Immunosuppression in Living Donor Kidney Transplant Recipients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic kidney disease stage KDIGO 4 or 5~* First kidney transplant from a living donor~* Age ≥ 18 years~* ABO compatible~* CDC-PRA \< 20%~* No donor-specific antibodies~* Negative CDC and ELISA crossmatch~* Immunosuppression with cyclosporin A, EC-MPS and methylprednisolone~* Informed consent~* Adequate contraception (women with child bearing potential)~Exclusion Criteria:~* Psychiatric disorder~* Heart failure (NYHA III or IV)~* Severe liver disease~* Active hepatitis B or C or HIV infection~* Active bacterial, fungal or viral disease~* Malignancy or malignancy in the last 5 years before screening~* Preexisting immunosuppression~* Vaccination with a live vaccine in the last 3 months before screening~* S/p splenectomy~* Substance abuse~* Pregnancy or lactation~* Women: Child/pregnancy with the intended donor~* Allergy against the investigational drug or part of it~* Other diseases that prohibit participation in the study (in the opinion of the investigator)~* Participation in an other interventional study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention arm (Type: EXPERIMENTAL): Patients receive MIC cell therapy together with standard immunosuppressive therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete